Jul. 11, 2024

JCR Affirmed AA+p on Astellas Pharma; Revised Outlook to Negative

May. 01, 2023

Astellas Pharma to Acquire a U.S. Company for Approx. USD 5.9 Billion - Finances Will Deteriorate, but Immediate Rating Revision Is Not Necessary

Sep. 07, 2022

JCR Affirmed AA+p/Stable Long-term Issuer Rating on Astellas Pharma

Jun. 15, 2022

Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2022

Jun. 01, 2021

Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2021

Oct. 23, 2020

JCR Affirmed AA+p/Stable Long-term Issuer Rating on Astellas Pharma

Jun. 17, 2020

Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2020

Dec. 03, 2019

Astellas Pharma Acquires US Biotechnology Firm - Limited Impact on Rating

Sep. 11, 2019

JCR Affirmed AA+p/Stable Long-term Issuer Rating on Astellas Pharma

Jun. 25, 2019

Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2019